GLP-1 Drugs Hit 78% Success Rate in Largest Meta-Analysis to Date

Out of every 100 people who take a GLP-1 drug for weight loss, about 78 will lose at least 5% of their body weight. On placebo, that number drops to 27. Those are the headline findings from a new meta-analysis covering 16 clinical trials and over 7,000 participants. (Ahmad et al., Medicine, March 13, 2026. PMID: 41824845)

The gap is massive. Patients on active treatment were 11 times more likely to hit the 5% threshold than those on placebo. That 5% mark matters because it's where doctors start seeing measurable improvements in blood pressure, blood sugar, and cardiovascular risk.

Tirzepatide pulled ahead of semaglutide

Both drugs work. But tirzepatide consistently outperformed semaglutide across the trials included in this analysis. The likely reason: tirzepatide hits two receptors (GLP-1 and GIP) while semaglutide only targets one.

That dual mechanism translates to more weight loss at comparable doses. It also means more side effects for some people, mostly nausea and vomiting, which leads to the next issue.

Higher doses work better but cost more dropouts

Tirzepatide at 15mg produced the best weight loss numbers in the analysis. It also had the highest dropout rate from gastrointestinal side effects. The 10mg dose landed in a sweet spot for most participants: strong results with fewer people quitting due to nausea.

Semaglutide trials went up to 2.4mg weekly (the Wegovy dose). Effective, but the tirzepatide data at 10mg and 15mg consistently beat it on percentage of body weight lost.

What 78% actually means in practice

These numbers come from controlled trials with screened participants, regular check-ins, and structured protocols. Real-world results are usually lower. People miss doses, eat differently than trial participants, and don't always have the same support structure.

The 78% also measures a specific outcome: 5% body weight loss. For someone at 250 lbs, that's 12.5 lbs. Meaningful, but most people starting a GLP-1 are hoping for more than that. The good news is that many trial participants exceeded the threshold significantly, particularly on higher tirzepatide doses.

A note on compounded versions

Every trial in this analysis used FDA-approved branded formulations (Mounjaro, Zepbound, Wegovy, Ozempic). Compounded tirzepatide and semaglutide may not deliver identical results. Potency can vary between compounding pharmacies, and the FDA has recently cracked down on several 503B facilities over quality concerns.

This doesn't mean compounded versions don't work. It means the 78% number comes from a specific product with verified dosing, and results with other formulations are harder to predict.

What this analysis doesn't answer

Trial durations ranged from 12 to 68 weeks. That's a wide spread. Someone on a 12-week trial and someone on a 68-week trial are in fundamentally different situations, and pooling their results together introduces noise.

The patient populations also varied. Some trials included people with type 2 diabetes, others excluded them. Baseline weights, ages, and health conditions differed across studies. These are standard limitations in meta-analyses, but worth flagging.

The analysis also didn't break down gastrointestinal side effect rates across drugs and doses. For anyone choosing between tirzepatide and semaglutide, tolerability is half the decision, and this study doesn't help with that comparison.

The bottom line on the data

GLP-1 drugs work for weight loss. That's no longer a question. This meta-analysis puts the clearest numbers yet on how well they work compared to placebo, and the answer is dramatically better. The remaining questions are about which drug, at what dose, for which patients, and whether the results hold up outside of clinical trial conditions.

For a deeper look at how these compounds compare, see our guides on tirzepatide and semaglutide.